[go: up one dir, main page]

PE20120082A1 - Derivados de (4-terc-butilpiperazin-2-il) (piperazin-1-il)metanona-n-carboxamida - Google Patents

Derivados de (4-terc-butilpiperazin-2-il) (piperazin-1-il)metanona-n-carboxamida

Info

Publication number
PE20120082A1
PE20120082A1 PE2011001229A PE2011001229A PE20120082A1 PE 20120082 A1 PE20120082 A1 PE 20120082A1 PE 2011001229 A PE2011001229 A PE 2011001229A PE 2011001229 A PE2011001229 A PE 2011001229A PE 20120082 A1 PE20120082 A1 PE 20120082A1
Authority
PE
Peru
Prior art keywords
terc
carboxamide
butylpiperazin
methanone
piperazin
Prior art date
Application number
PE2011001229A
Other languages
English (en)
Inventor
John Cumming
Alan Wllington Faull
David Waterson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20120082A1 publication Critical patent/PE20120082A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/195—Radicals derived from nitrogen analogues of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A UN COMPUESTO DERIVADO DE CARBOXAMIDA TAL COMO 4-[(2R)-4-TERC-BUTILPIPERAZINA-2-CARBONIL]-N-(4-CLORO-3-FLUOROFENIL)PIPERAZINA-1-CARBOXAMIDA, 4-[(2R)-4-TERC-BUTILPIPERAZINA-2-CARBONIL]-N-[3-(TRIFLUOROMETIL)FENIL]PIPERAZINA-1-CARBOXAMIDA, 4-[(2R)-4-TERC-BUTILPIPERAZINA-2-CARBONIL]-N-(3-CLOROFENIL)PIPERAZINA-1-CARBOXAMIDA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR CCR2b Y SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS Y/O DOLOR NEUROPATICO
PE2011001229A 2008-12-15 2009-12-14 Derivados de (4-terc-butilpiperazin-2-il) (piperazin-1-il)metanona-n-carboxamida PE20120082A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12244508P 2008-12-15 2008-12-15

Publications (1)

Publication Number Publication Date
PE20120082A1 true PE20120082A1 (es) 2012-03-04

Family

ID=42241254

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001229A PE20120082A1 (es) 2008-12-15 2009-12-14 Derivados de (4-terc-butilpiperazin-2-il) (piperazin-1-il)metanona-n-carboxamida

Country Status (24)

Country Link
US (3) US20100152197A1 (es)
EP (2) EP2727913A1 (es)
JP (1) JP2012512153A (es)
KR (1) KR20110099012A (es)
CN (1) CN102317273A (es)
AR (1) AR074737A1 (es)
AU (1) AU2009327575B2 (es)
BR (1) BRPI0922439A2 (es)
CA (1) CA2746990A1 (es)
CL (1) CL2011001436A1 (es)
CO (1) CO6440554A2 (es)
CR (1) CR20110332A (es)
CU (1) CU20110133A7 (es)
DO (1) DOP2011000191A (es)
EA (1) EA201190019A1 (es)
EC (1) ECSP11011131A (es)
IL (1) IL213163A0 (es)
MX (1) MX2011006087A (es)
NI (1) NI201100125A (es)
PE (1) PE20120082A1 (es)
TW (1) TW201028400A (es)
UY (1) UY32321A (es)
WO (1) WO2010071567A1 (es)
ZA (1) ZA201105219B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070091677A (ko) 2004-12-24 2007-09-11 아스트라제네카 아베 Ｃｃｒ2ｂ 길항제로서의 헤테로시클릭 화합물
GB0525957D0 (en) * 2005-12-21 2006-02-01 Astrazeneca Ab Methods
WO2018134731A1 (en) 2017-01-17 2018-07-26 Glaxosmithkline Intellectual Property Development Limited Non peptidic heterobivalent molecules for treating inflammatory diseases
US12319958B2 (en) 2020-07-21 2025-06-03 Rutgers, The State University Of New Jersey Method and kit for CCR2 expression profiling and disease stratification

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133061A (en) * 1962-11-13 1964-05-12 Sterling Drug Inc Piperidine carboxamides and derivatives thereof
US3541085A (en) * 1969-05-09 1970-11-17 American Cyanamid Co Method of preparing thiotricyclic compounds
DE4234295A1 (de) * 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
BR9707495A (pt) 1996-02-13 1999-07-27 Zeneca Ltd Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
JP4464466B2 (ja) 1996-03-05 2010-05-19 アストラゼネカ・ユーケイ・リミテッド ４―アニリノキナゾリン誘導体
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
DE19743435A1 (de) * 1997-10-01 1999-04-08 Merck Patent Gmbh Benzamidinderivate
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
JP2004502766A (ja) 2000-07-07 2004-01-29 アンギオジェン・ファーマシューティカルズ・リミテッド 血管損傷剤としてのコルヒノール誘導体
CA2410562A1 (en) 2000-07-07 2002-01-31 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
US20060205761A1 (en) 2003-06-06 2006-09-14 Catherine Abbadie Ccr-2 antagonists for treatment of neuropathic pain
GB0428327D0 (en) * 2004-12-24 2005-02-02 Astrazeneca Ab Method
KR20070091677A (ko) * 2004-12-24 2007-09-11 아스트라제네카 아베 Ｃｃｒ2ｂ 길항제로서의 헤테로시클릭 화합물
GB0525957D0 (en) * 2005-12-21 2006-02-01 Astrazeneca Ab Methods

Also Published As

Publication number Publication date
KR20110099012A (ko) 2011-09-05
CR20110332A (es) 2011-08-05
AU2009327575B2 (en) 2013-07-04
CA2746990A1 (en) 2010-06-24
ECSP11011131A (es) 2011-07-29
AU2009327575A1 (en) 2011-06-23
UY32321A (es) 2010-07-30
EP2379519A1 (en) 2011-10-26
US20130289043A1 (en) 2013-10-31
US20120289513A1 (en) 2012-11-15
US20100152197A1 (en) 2010-06-17
NI201100125A (es) 2012-03-19
MX2011006087A (es) 2011-06-21
WO2010071567A1 (en) 2010-06-24
CN102317273A (zh) 2012-01-11
BRPI0922439A2 (pt) 2017-06-06
CO6440554A2 (es) 2012-05-15
ZA201105219B (en) 2012-03-28
DOP2011000191A (es) 2011-07-15
EA201190019A1 (ru) 2012-02-28
CL2011001436A1 (es) 2011-08-26
EP2727913A1 (en) 2014-05-07
IL213163A0 (en) 2011-07-31
CU20110133A7 (es) 2012-01-31
EP2379519A4 (en) 2012-06-20
AR074737A1 (es) 2011-02-09
JP2012512153A (ja) 2012-05-31
TW201028400A (en) 2010-08-01

Similar Documents

Publication Publication Date Title
PE20110298A1 (es) Derivados de picolinamida como inhibidores de cinasa
CL2011001082A1 (es) Compuestos derivados de amino-tetrahidropiranos sustituidos con heterociclos, composicion farmaceutica; y uso en el tratamiento de una afeccion seleccionada de resistencia a la insulina, hiperglicemia y diabetes de tipo 2.
PE20110062A1 (es) N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo
PE20130340A1 (es) (r)-n-(3-(7-metil-1h-indazol-5-il)-1-(4-metilpiperidin-4-il)piperazin-1-il)-1-oxopropan-2-il)-4-(2-oxo-1,2-dihidroquinolin-3-il)piperidina-1-carboxamida como antagonista del receptor de peptido relacionado con el gen de la calcitonina (cgrp)
PE20170695A1 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasas
PE20142185A1 (es) Pirrolidina-2-carboxamidas sustituidas
PE20090772A1 (es) Derivados de bencimidazol
PE20141855A1 (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
CL2008001114A1 (es) Compuestos derivados de bencimidazol; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como vejiga sobreactiva, dolor, obesidad, convulsiones, entre otras.
EA200801738A1 (ru) Пиперидиноилпирролидиновые агонисты меланокортинового рецептора 4 типа
CO6321273A2 (es) N-fenil -y - lactamas subtituidas las cuales son agonistas ep2 para ser usados como agentes terapeuticos para el tratamiento de glaucoma, sindrome del intestino irritable y calvicie
PE20121617A1 (es) Derivados de oxazina como inhibidores de bace
UA107814C2 (uk) Спірооксіндольні антагоністи мdм2
CO6561821A2 (es) Compuesto n-(1h-indazol-4-il)imidazol[1.2-a]piridin -3-carboxamida sustituidos como inhibidores de cfms
PA8779701A1 (es) Imidazopiridazinas sustituidas como inhibidores de cinasa de lipido
PE20161363A1 (es) Moduladores del receptor acoplado a la proteina g40 (gpr40) de pirrolidina para el tratamiento de enfermedades como la diabetes
MX376062B (es) Agonistas del receptor muscarinico.
PE20081409A1 (es) Antagonistas del receptor de progesterona
PE20150709A1 (es) Benzamidas
GB2511685A (en) Muscarinic m1 receptor agonists
EA201170722A1 (ru) Лактамы в качестве ингибиторов бета-секретазы
ECSP10010428A (es) Derivados de indazol
ECSP066991A (es) 3-(4-heteroarilciclohexilamino)ciclopentanocarboxamidas como moduladores de receptores de quimiocinas
PE20091032A1 (es) Composicion que contiene n-(3-metoxi-5-metilpirazin-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil)piridin-3-sulfonamida (zibotentan)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal